reports
Corindus Vascular Robotics, Inc. Stockholders Approve Acquisition by S...
WALTHAM, Mass.--(BUSINESS WIRE)-- At a special meeting today, stockholders of Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS) approved the adoption of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 7, 2019, by and among Siemens Medical Solutions USA, Inc. (“SMS USA”), Corpus Merger Inc. (“Merger Sub”) and Corindus. Subject to the terms and conditions of the Merger Agreement, Merger Sub, a wholly owned subsidiary of SMS USA, will be merged with and into Corindus, with Corindus surviving the merger as a wholly owned subsidiary o...
Corindus to Showcase CorPath® GRX System at Transcatheter Cardiovascu...
WALTHAM, Mass.,--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it will showcase the capabilities of the CorPath® GRX system at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 Conference, to be held September 25-29 in San Francisco, California. CorPath GRX is the only U.S. Food and Drug Administration (“FDA”) cleared and CE-marked medical device for robotic-assisted vascular interventions. At Corindus’ booth 1327, attendees will be able to gain hands-on experience with CorPath GRX in an advanc...
First-in-Human Telerobotic Coronary Intervention Procedures Published ...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has published the results from the , the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catheterization lab using Corindus’ CorPath technology platform. The paper, titled Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience, d...
Corindus Reports Second Quarter 2019 Results
WALTHAM, Mass.--(BUSINESS WIRE)-- , Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2019. Corindus also announced today that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggr...
Corindus Vascular Robotics Announces Definitive Agreement to Be Acquir...
WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion. “We are pleased to ...
Corindus to Present at Canaccord Genuity 39th Annual Growth Conference...
WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will present at the Canaccord Genuity 39th Annual Growth Conference as follows: Date: Thursday, August 8, 2019 Time: 3:30 p.m. EDT Location: InterContinental Boston, Boston Webcast: The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the company’s webs...
Corindus to Report Second Quarter 2019 Financial Results on August 8, ...
WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release second quarter 2019 financial and business results on Thursday, August 8, 2019 before the open of the U.S. financial markets. Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, August 8, 2019 Time 8:30 a.m. EDT Toll free (U.S.) (833) 286-5802 Intern...
Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Faci...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has installed CorPath® GRX Systems in two new hospitals affiliated with one of the nation’s largest hospital networks, . The new systems are now installed in hospital locations in Florida and Texas, bringing the total number of HCA hospitals utilizing CorPath GRX to three. “We are pleased with HCA Healthcare’s continued commitment to our CorPath GRX technology and the work we are doing to bring next-generation robotic solutions to...
Corindus Announces Regulatory Approval of CorPath GRX for Neurovascula...
WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received approval from the Australian Therapeutic Goods Administration to commercialize its CorPath® GRX System for neurovascular interventions in Australia and New Zealand. The CorPath GRX System is already approved for percutaneous coronary and peripheral vascular interventions in the region. In March 2019, Corindus received CE mark to commercialize CorPath GRX for neurovascular interventions in 33 countries in Europe and the ...
Corindus Announces First Commercial Installation of CorPath® GRX Syst...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company's technology in its health system’s leading research facilities. “Our hospital has a long history of innovation and...
Corindus Joins Russell 3000® Index
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-ca...
Corindus CorPath GRX System Successfully Used in Live Complex Robotic-...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the Conference in Paris, France on Wednesday, May 22, 2019. Interventional Cardiologist, PCR Vice-Chairman, and Course Director of EuroPCR, Dr. Jean Fajadet performed the procedure from in Toulouse, France. It was broadcast live to EuroPCR ...
Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019. Corindus will use the annual meeting at EuroPCR 2019 to highlight recent milestones in technology development, including the latest CE marked technIQ™ Smart Procedural Automation, automated movements aimed at improving navigation, lesion crossing, and...
Corindus to Present “Evolution of Robotics: Automation, Remote Appli...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, will sponsor a breakfast symposium on May 21, 2019 titled, “Evolution of Robotics: Automation, Remote Applications, and Beyond,” during the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions. The breakfast will be held in the Castellana Ballroom 1 at the Cosmopolitan of Las Vegas in Las Vegas, NV from 6:45 a.m. to 7:45 a.m. PDT. Chaired by Mani...
Corindus Reports First Quarter 2019 Results
WALTHAM, Mass.--(BUSINESS WIRE)-- , Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its first quarter ended March 31, 2019. Recent Financial Highlights and Business Accomplishments: Revenue totaled $3.0 million during the first quarter of 2019, including sale and installation of nine CorPath GRX Systems; Recorded purchase orders for 11 CorPath GRX Systems, an increase of 83% compared to purchase orders received in Q4 2018...
Corindus Equips the World’s First Fully Robotic Catheterization Labo...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital in the world to adopt vascular robotic systems in all vascular intervention treatment rooms. The outfitted labs will allow physicians to leverage the latest robotic technolog...
Corindus to Report First Quarter 2019 Financial Results on May 7, 2019
WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S. financial markets. Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will host a conference call to discuss the results as follows: Date ...
Corindus Announces First Robotic-Assisted Interventions in Japan for C...
WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. These procedures mark initial enrollment in a post-market study of CorPath GRX in Japan. CorPath GRX received Pharmaceutical and Medical Device Agency (PMDA) a...
Corindus Vascular Robotics Files Required Registration Statement for H...
WALTHAM, Mass.--(BUSINESS WIRE)-- , Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it filed a registration statement on behalf of investors that participated in its recently completed private placement. As previously disclosed, earlier this quarter, Corindus sold shares of its common stock to a large institutional investor and certain existing stockholders with contractual preemptive rights, including Hudson Executive Capital (“HEC”) and BioStar Ventur...
- Jonathan Moreland
WDC WESTERN DIGITAL CORPORATION
URBN URBAN OUTFITTERS INC.
TNAV TELENAV
SYNL SYNALLOY CORP.
STON STONEMOR INC.
RPT RAMCO-GERSHENSON PROPERTIES TRUST
PRGX PRGX GLOBAL
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
OCUL OCULAR THERAPEUTIX
LION FIDELITY SOUTHERN CORP.
LGND LIGAND PHARMACEUTICALS INCORPORATED
KOP KOPPERS HOLDINGS INC.
HCI HCI GROUP INC.
GARS GARRISON CAPITAL INC.
FFIN FIRST FINANCIAL BANKSHARES INC
EVH EVOLENT HEALTH INC CLASS A
ESGR ENSTAR GROUP LIMITED
DFRG DEL FRISCO'S RESTAURANT GROUP
CVS CVS HEALTH CORPORATION
CVRS CORINDUS VASCULAR ROBOTICS
CSU CAPITAL SENIOR LIVING CORPORATION
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC
CORT CORCEPT THERAPEUTICS INCORPORATED.
BECN BEACON ROOFING SUPPLY INC.
ATVI ACTIVISION BLIZZARD INC.
ARTX AROTECH
AKAO ACHAOGEN INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ACRX ACELRX PHARMACEUTICALS
ACRE ARES COMMERCIAL REAL ESTATE
ATEC ALPHATEC HOLDINGS INC.
ATRO ASTRONICS CORPORATION
CERC CERECOR INC
CULP CULP INC.
MGM MGM RESORTS INTERNATIONAL
FIZZ NATIONAL BEVERAGE CORP.
OTEL OTELCO INC
PMD PSYCHEMEDICS CORP.
IDSY I.D. SYSTEMS INC.
HAIN THE HAIN CELESTIAL GROUP
RIBT INC.
WOW RICEBRAN TECHNOLOGIES
CGBD WIDEOPENWEST INC.
ODT TCG BDC
APLS ODONATE THERAPEUTICS INC
MAXR APELLIS PHARMACEUTICALS
SFIX MAXAR TECHNOLOGIES INC.
RDVT STITCH FIX CLASS A
AMRX RED VIOLET
RNDB AMNEAL PHARMACEUTICALS INC. CLASS A
REZI RANDOLPH BANCORP
CTT RESIDEO TECHNOLOGIES
INC.
WELLS TIMBERLAND REIT
INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.